The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers
Open accessAbstract
Breast cancers lacking estrogen and progesterone receptor expression and Her2 amplification exhibit distinct gene expression profiles and clinical features, and they comprise the majority of BRCA1-associated tumors. Here we demonstrated that the p53 family member p63 controls a pathway for p73-dependent cisplatin sensitivity specific to these "triple-negative" tumors. In vivo, DeltaNp63 and TAp73 isoforms were coexpressed exclusively within a subset of triple-negative primary breast cancers that commonly exhibited mutational inactivation of p53. The DeltaNp63alpha isoform promoted survival of breast cancer cells by binding TAp73 and thereby inhibiting its proapoptotic activity. Consequently, inhibition of p63 by RNA interference led to TAp73-dependent induction of proapoptotic Bcl-2 family members and apoptosis. Breast cancer cells expressing DeltaNp63alpha and TAp73 exhibited cisplatin sensitivity that was uniquely dependent on TAp73. Thus, in response to treatment with cisplatin, but not other chemotherapeutic agents, TAp73 underwent c-Abl-dependent phosphorylation, which promoted dissociation of the DeltaNp63alpha/TAp73 protein complex, TAp73-dependent transcription of proapoptotic Bcl-2 family members, and apoptosis. These findings define p63 as a survival factor in a subset of breast cancers; furthermore, they provide what we believe to be a novel mechanism for cisplatin sensitivity in these triple-negative cancers, and they suggest that such cancers may share the cisplatin sensitivity of BRCA1-associated tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., & Green, D. R. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1545 · Cited by 2,824
p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development
Yang, A., Schweitzer, R., Sun, D., Kaghad, M., Walker, N., Bronson, R. T., Tabin, C., Sharpe, A., Caput, D., Crum, C., et al. (1999) · Nature · doi:10.1038/19539 · Cited by 2,225
Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
p63 is a p53 homologue required for limb and epidermal morphogenesis
Mills, A. A., Zheng, B., Wang, X.-J., Vogel, H., Roop, D. R., & Bradley, A. (1999) · Nature · doi:10.1038/19531 · Cited by 1,988
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
Livasy, C. A., Karaca, G., Nanda, R., Tretiakova, M. S., Olopade, O. I., Moore, D. T., & Perou, C. M. (2006) · Modern Pathology · doi:10.1038/modpathol.3800528 · Cited by 1,063
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
Gong, J., Costanzo, A., Yang, H.-Q., Melino, G., Kaelin, W. G., Levrero, M., & Wang, J. Y. J. (1999) · Nature · doi:10.1038/21690 · Cited by 930
Gene expression profiles of human breast cancer progression
Ma, X.-J., Salunga, R., Tuggle, J. T., Gaudet, J., Enright, E., McQuary, P., Payette, T., Pistone, M., Stecker, K., Zhang, B. M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931261100 · Cited by 887
Self-citationBasu, S., Totty, N. F., Irwin, M. S., Sudol, M., & Downward, J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(02)00776-1 · Cited by 843 · cited 1×
“These include AKT-dependent coactivator recruitment (45, 46), Chk1/2-dependent induction of p73 mRNA (47), and c-Abl–dependent phosphorylation (35, 37, 38).”
BackgroundRe: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., et al. (2006) · JAMA · doi:10.1001/jama.295.14.1658 · Cited by 731
P53 expression in breast cancer
Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L., & Delia, D. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910410204 · Cited by 601
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
Yuan, Z.-M., Shioya, H., Ishiko, T., Sun, X., Gu, J., Huang, Y., Lu, H., Kharbanda, S., Weichselbaum, R., & Kufe, D. (1999) · Nature · doi:10.1038/21704 · Cited by 578
Interaction of c-Abl and p73α and their collaboration to induce apoptosis
Agami, R., Blandino, G., Oren, M., & Shaul, Y. (1999) · Nature · doi:10.1038/21697 · Cited by 546
Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yulug, I., Merlano, M., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 449
p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis
Rocco, J. W., Leong, C.-O., Kuperwasser, N., DeYoung, M. P., & Ellisen, L. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.013 · Cited by 433
Self-citationChemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408
p63 regulates an adhesion programme and cell survival in epithelial cells
Carroll, D. K., Carroll, J. S., Leong, C.-O., Cheng, F., Brown, M., Mills, A. A., Brugge, J. S., & Ellisen, L. W. (2006) · Nature Cell Biology · doi:10.1038/ncb1420 · Cited by 403
Self-citationp73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation
Melino, G., Bernassola, F., Ranalli, M., Yee, K., Zong, W. X., Corazzari, M., Knight, R. A., Green, D. R., Thompson, C., & Vousden, K. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m307469200 · Cited by 368
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells
Tassone, P., Tagliaferri, P., Perricelli, A., Blotta, S., Quaresima, B., Martelli, M. L., Goel, A., Barbieri, V, Costanzo, F., Boland, C. R., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600859 · Cited by 361
Strano, S., Monti, O., Pediconi, N., Baccarini, A., Fontemaggi, G., Lapi, E., Mantovani, F., Damalas, A., Citro, G., Sacchi, A., et al. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.008 · Cited by 360
Significance of p63 amplification and overexpression in lung cancer development and prognosis.
Massion, P. P., Taflan, P. M., Rahman, S. M. J., Yildiz, P., Shyr, Y., Edgerton, M. E., Westfall, M. D., Roberts, J. R., Pietenpol, J. A., Carbone, D. P., et al. (2003) · PubMed · Cited by 320
BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants
Elstrodt, F., Hollestelle, A., Nagel, J. H. A., Gorin, M., Wasielewski, M., van den Ouweland, A., Merajver, S. D., Ethier, S. P., & Schutte, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2853 · Cited by 305
The common and distinct target genes of the p53 family transcription factors
Harms, K., Nozell, S., & Chen, X. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3304-4 · Cited by 295
Myoepithelial cells: good fences make good neighbors
Adriance, M. C., Inman, J. L., Petersen, O. W., & Bissell, M. J. (2005) · Breast Cancer Research · doi:10.1186/bcr1286 · Cited by 262
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2
Urist, M., Tanaka, T., Poyurovsky, M. V., & Prives, C. (2004) · Genes & Development · doi:10.1101/gad.1221004 · Cited by 234
p63 Expression in Breast Cancer: A Highly Sensitive and Specific Marker of Metaplastic Carcinoma
Koker, M. M., & Kleer, C. G. (2004) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000138183.97366.fd · Cited by 220
Platinum-based chemotherapy in metastatic breast cancer: current status
Decatris, M. P., Sundar, S., & O’Byrne, K. J. (2004) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00139-7 · Cited by 211
Wang, Z. C., Lin, M., Wei, L.-J., Li, C., Miron, A., Lodeiro, G., Harris, L., Ramaswamy, S., Tanenbaum, D. M., Meyerson, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2570 · Cited by 190
Pin1 Links the Activities of c-Abl and p300 in Regulating p73 Function
Mantovani, F., Piazza, S., Gostissa, M., Strano, S., Zacchi, P., Mantovani, R., Blandino, G., & Del Sal, G. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.05.007 · Cited by 181
How Many Mutant p53 Molecules Are Needed To Inactivate a Tetramer?
Chan, W. M., Siu, W. Y., Lau, A., & Poon, R. Y. C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3536-3551.2004 · Cited by 158
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Wistuba, I. I., Behrens, C., Milchgrub, S., Syed, S., Ahmadian, M., Virmani, A. K., Kurvari, V., Cunningham, T. H., Ashfaq, R., Minna, J. D., et al. (1998) · PubMed · Cited by 147
King, K. E., Ponnamperuma, R. M., Yamashita, T., Tokino, T., Lee, L. A., Young, M. F., & Weinberg, W. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206536 · Cited by 142
Tumor-Specific p73 Up-regulation Mediates p63 Dependence in Squamous Cell Carcinoma
DeYoung, M. P., Johannessen, C. M., Leong, C., Faquin, W. C., Rocco, J. W., & Ellisen, L. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1619 · Cited by 133
Self-citationDominant Negative p63 Isoform Expression in Head and Neck Squamous Cell Carcinoma
Sniezek, J. C., Matheny, K. E., Westfall, M. D., & Pietenpol, J. A. (2004) · The Laryngoscope · doi:10.1097/01.mlg.0000149437.35855.4b · Cited by 132
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
Druker, B. J. (2002) · Oncogene · doi:10.1038/sj.onc.1206081 · Cited by 130
Elevated expression of p63 protein in human esophageal squamous cell carcinomas
Hu, H., Xia, S., Li, A., Xu, X., Cai, Y., Han, Y., Wei, F., Chen, B., Huang, X., Han, Y., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10739 · Cited by 123
Fomenkov, A. I., Zangen, R., Huang, Y., Osada, M., Guo, Z., Fomenkov, T., Trink, B., Sidransky, D., & Ratovitski, E. A. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1155 · Cited by 117
Domínguez, G., García, J. M., Peña, C., Silva, J., García‐Barberán, V., Martínez, L., Maximiano, C., Gomez, M. E., Rivera, J. A., García-Andrade, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2350 · Cited by 112
c-Abl stabilizes p73 by a phosphorylation-augmented interaction.
Tsai, K. K., & Yuan, Z.-M. (2003) · PubMed · Cited by 93
Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols
Bradshaw, T. D., Matthews, C. S., Cookson, J. C., Chew, E., Shah, M. A., Bailey, K., Monks, A. P., Harris, E. D., Westwell, A. D., Wells, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4141 · Cited by 85
ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin
Zangen, R., Ratovitski, E. A., & Sidransky, D. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2066 · Cited by 84
Weber, A., Bellmann, U., Bootz, F., Wittekind, C., & Tannapfel, A. (2002) · International Journal of Cancer · doi:10.1002/ijc.10296 · Cited by 79
P63 expression in normal, hyperplastic and malignant breast tissues
Wang, X., Mori, I., Tang, W., Nakamura, M., Nakamura, Y., Sato, M., Sakurai, T., & Kakudo, K. (2002) · Breast Cancer · doi:10.1007/bf02967592 · Cited by 78
Truong, T., Sun, G., Doorly, M., Wang, J. Y. J., & Schwartz, M. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1635435100 · Cited by 67
Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer
Domínguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sánchez, A., Navarro, A., Gallego, I., Provencio, M., España, P., & Bonilla, F. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010624717311 · Cited by 57
Cited by
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C.-O., Calogrias, D., Buraimoh, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4725 · Cited by 981
Self-citationTriple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Cellular Responses to Cisplatin‐Induced DNA Damage
Basu, A., & Krishnamurthy, S. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/201367 · Cited by 569
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors
Xu, J., Reumers, J., Couceiro, J. R., De Smet, F., Gallardo, R., Rudyak, S., Cornelis, A., Rozenski, J., Zwolinska, A., Marine, J.-C., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.546 · Cited by 543
Metadata
- Authors
- Leong, C.-O., Vidnovic, N., DeYoung, M. P., Sgroi, D., & Ellisen, L. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2007-05-01
- Volume
- 117
- Issue
- 5
- Pages
- 1370-1380
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2022289852
- Cited by
- 270
- References
- 52
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.